None of the 29 investors followed here reported a position in LTGO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LTGO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 9, 2026 | Sanofi SaBeneficial Owner of more than 10% of a Class of Security | — | 672.8K | — |
| Aug 9, 2026 | Seidenberg Beth CDirector and Beneficial Owner of more than 10% of a Class of Security | — | 12.70M | — |
| Aug 9, 2026 | 5am Ventures Vi, L.P.Beneficial Owner of more than 10% of a Class of Security | — | 7.33M | — |
| Aug 9, 2026 | Tananbaum James BDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 140K | $2.52M |
| Aug 9, 2026 | Tananbaum James BDirector and Beneficial Owner of more than 10% of a Class of Security | — | 9.04M | — |
| Aug 9, 2026 | Foresite Capital Management V, Llc.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 18.00 per share. | 140K | $2.52M |
| Aug 9, 2026 | Foresite Capital Management V, Llc.Beneficial Owner of more than 10% of a Class of Security | — | 9.04M | — |
| Aug 9, 2026 | Westlake Biopartners Fund I, L.P.Beneficial Owner of more than 10% of a Class of Security | — | 12.70M | — |
Buy / hold / sell counts
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.